Inventor
CHAPLIN PAUL
DE39 patents
⚠️ This page may combine multiple inventors who share the name “CHAPLIN PAUL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BAVARIAN NORDIC AS
29 patentsUS7335364B2Feb 26, 2008
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS58 citations98
US6913752B2Jul 5, 2005
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS106 citations98
US6761893B2Jul 13, 2004
Modified vaccinia ankara virus variant
BAVARIAN NORDIC AS222 citations98
US7445924B2Nov 4, 2008
Modified Vaccinia Ankara virus variant and cultivation method
BAVARIAN NORDIC AS63 citations97
US7964396B2Jun 21, 2011
Modified vaccinia ankara virus variant and cultivation method
BAVARIAN NORDIC AS30 citations96
US7964395B2Jun 21, 2011
Modified vaccinia ankara virus variant and cultivation method
BAVARIAN NORDIC AS30 citations96
US7964398B2Jun 21, 2011
Modified vaccinia ankara virus variant and cultivation method
BAVARIAN NORDIC AS28 citations96
US7939086B2May 10, 2011
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS32 citations96
US7923017B2Apr 12, 2011
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS32 citations96
US7459270B2Dec 2, 2008
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS39 citations96
US7384644B2Jun 10, 2008
Modified Vaccinia Ankara virus variant
BAVARIAN NORDIC AS54 citations96
US7097842B2Aug 29, 2006
Modified vaccinia virus ankara for the vaccination of neonates
BAVARIAN NORDIC AS87 citations96
US7189536B2Mar 13, 2007
Modified vaccinia ankara virus variant
BAVARIAN NORDIC AS56 citations95
US8029800B2Oct 4, 2011
Recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
BAVARIAN NORDIC AS12 citations92
US8021669B2Sep 20, 2011
Methods for inducing an immune response in a host comprising administering modified vaccinia virus ankara (MVA) recombinants comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
BAVARIAN NORDIC AS21 citations92
US7501127B2Mar 10, 2009
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
BAVARIAN NORDIC AS26 citations92
US8372622B2Feb 12, 2013
Modified vaccinia virus ankara for the vaccination of neonates
BAVARIAN NORDIC AS23 citations91
US7892533B2Feb 22, 2011
Modified vaccinia virus ankara for the vaccination of neonates
BAVARIAN NORDIC AS26 citations91
US7628980B2Dec 8, 2009
Modified vaccinia virus ankara for the vaccination of neonates
BAVARIAN NORDIC AS30 citations91
US7897156B2Mar 1, 2011
Modified vaccinia virus ankara for the vaccination of neonates
BAVARIAN NORDIC AS22 citations87
US9463238B2Oct 11, 2016
Recombinant poxvirus vector comprising tetanus toxin fragment C
BAVARIAN NORDIC AS3 citations73
US10946089B2Mar 16, 2021
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
BAVARIAN NORDIC AS0 citations61
US9265823B2Feb 23, 2016
Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
BAVARIAN NORDIC AS2 citations58
US10532094B2Jan 14, 2020
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
BAVARIAN NORDIC AS0 citations50
US10124058B2Nov 13, 2018
Recombinant modified vaccinia virus Ankara (MVA) Respiratory Syncytial Virus (RSV) vaccine
BAVARIAN NORDIC AS0 citations50
US10111946B2Oct 30, 2018
Poxviral vectors for low antibody response after a first priming immunization
BAVARIAN NORDIC AS0 citations50
US9717787B2Aug 1, 2017
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
BAVARIAN NORDIC AS0 citations50
US9480738B2Nov 1, 2016
Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
BAVARIAN NORDIC AS0 citations50
US9707291B2Jul 18, 2017
Single high dose of MVA induces a protective immune response in neonates and infants
BAVARIAN NORDIC AS0 citations49
CHAPLIN PAUL
6 patentsUS8268329B2Sep 18, 2012
Modified Vaccinia ankara virus variant
CHAPLIN PAUL28 citations96
US8268325B2Sep 18, 2012
Modified Vaccinia Ankara virus variant
CHAPLIN PAUL23 citations96
US8470598B2Jun 25, 2013
Modified Vaccinia Ankara virus variant and cultivation method
CHAPLIN PAUL23 citations92
US8236560B2Aug 7, 2012
Modified Vaccinia Ankara virus variant and cultivation method
CHAPLIN PAUL24 citations92
US8163293B2Apr 24, 2012
Modified Vaccinia Virus Ankara for the vaccination of neonates
CHAPLIN PAUL30 citations92
US8808709B2Aug 19, 2014
Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
CHAPLIN PAUL4 citations68
HOWLEY PAUL
4 patentsUS8309098B2Nov 13, 2012
Recombinant modified vaccinia ankara (MVA) virus containing heterologous DNA inserts encoding human immunodeficiency virus (HIV) antigens inserted into one or more intergenic regions (IGRs)
HOWLEY PAUL33 citations96
US8197822B2Jun 12, 2012
Method for the production of human immunodeficiency virus (HIV) proteins utilizing modified vaccinia virus ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
HOWLEY PAUL6 citations84
US8323661B2Dec 4, 2012
Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
HOWLEY PAUL3 citations74
US8198088B2Jun 12, 2012
Method for introducing human immunodeficiency virus nucleotide sequences into a cell utilizing modified vaccinia virus Ankara (MVA) recombinants comprising HIV genes inserted into one or more intergenic regions (IGRs)
HOWLEY PAUL5 citations74